Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the upcoming Ladenburg Oncology Innovators & Investors Symposium.
CFO Raphi Levy will represent the company at this virtual event, scheduled for December 12, 2024, from 11:00 AM to 11:25 AM EST. The format will include both a presentation and one-on-one meetings, which can be arranged through Ladenburg representatives.
Alpha Tau Medical (NASDAQ: DRTS), sviluppatore della terapia al cobalto Alpha DaRT® per il cancro, ha annunciato la sua partecipazione al prossimo Ladenburg Oncology Innovators & Investors Symposium.
Il CFO Raphi Levy rappresenterà l'azienda in questo evento virtuale, programmato per il 12 dicembre 2024, dalle 11:00 alle 11:25 EST. Il formato prevede sia una presentazione che incontri individuali, che possono essere organizzati tramite i rappresentanti di Ladenburg.
Alpha Tau Medical (NASDAQ: DRTS), desarrollador de la terapia contra el cáncer de radiación alfa Alpha DaRT®, ha anunciado su participación en el próximo Ladenburg Oncology Innovators & Investors Symposium.
El CFO Raphi Levy representará a la empresa en este evento virtual, programado para el 12 de diciembre de 2024, de 11:00 AM a 11:25 AM EST. El formato incluirá tanto una presentación como reuniones individuales, que se pueden organizar a través de los representantes de Ladenburg.
알파 타우 메디컬 (NASDAQ: DRTS), 알파 방사선 암 치료의 개발업체인 Alpha DaRT®,가 곧 있을 Ladenburg Oncology Innovators & Investors Symposium에 참여한다고 발표했습니다.
CFO 라피 레비가 이 가상 행사에서 회사를 대표하며, 행사는 2024년 12월 12일 오전 11시부터 오전 11시 25분(EST)까지 예정되어 있습니다. 형식은 발표와 일대일 회의를 포함하며, 이는 Ladenburg 대표를 통해 조정할 수 있습니다.
Alpha Tau Medical (NASDAQ: DRTS), développeur de la thérapie contre le cancer à radiation alpha Alpha DaRT®, a annoncé sa participation au prochain Ladenburg Oncology Innovators & Investors Symposium.
Le CFO Raphi Levy représentera la société lors de cet événement virtuel, prévu le 12 décembre 2024, de 11h00 à 11h25 EST. Le format comprendra à la fois une présentation et des réunions individuelles, qui peuvent être organisées par l'intermédiaire des représentants de Ladenburg.
Alpha Tau Medical (NASDAQ: DRTS), Entwickler der Alpha DaRT® Alpha-Strahlungstherapie gegen Krebs, hat seine Teilnahme am bevorstehenden Ladenburg Oncology Innovators & Investors Symposium angekündigt.
Der CFO Raphi Levy wird das Unternehmen bei dieser virtuellen Veranstaltung vertreten, die für den 12. Dezember 2024 von 11:00 bis 11:25 Uhr EST angesetzt ist. Das Format umfasst sowohl eine Präsentation als auch Einzelgespräche, die über Vertreter von Ladenburg organisiert werden können.
- None.
- None.
JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium.
| Event: | Ladenburg Oncology Innovators & Investors Symposium |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | December 12, 2024 |
| Time: | 11:00AM – 11:25AM EST |
| Location: | Virtual |
Please reach out to your Ladenburg representative to schedule 1-on-1 meetings with Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact: IR@alphatau.com
FAQ
When is Alpha Tau Medical (DRTS) presenting at the Ladenburg Oncology Symposium?
Who will represent Alpha Tau Medical (DRTS) at the Ladenburg Symposium?
What is the format of Alpha Tau's (DRTS) participation in the Ladenburg Symposium?
How can investors arrange meetings with Alpha Tau (DRTS) at the Ladenburg Symposium?
